4 matches for your search in the start-up spotlight
rss
Collaboration leverages Iktos’ capabilities in machine learning and AI and Zealand expertise in peptide drug discovery
23-Jun-2022
Iktos, a company specialized in Artificial Intelligence for new drug design, announced a research collaboration with Zealand Pharma A/S, a biotechnology company changing lives with innovative peptide-based medicines to co-develop generative and predictive AI technologies for peptide drug ...
Rapid identification of molecules that simultaneously satisfy multiple parameters, such as potency, selectivity, safety, and project-specific properties
05-Apr-2022
Iktos, a company specialized in Artificial Intelligence (AI) for new drug design announced a collaboration agreement with Ono Pharmaceuticals Co., Ltd., a leading pharmaceutical company based in Japan with a focus on innovative medicines dedicated to the fight against disease and pain. Under the ...
“We are proud to work with Pfizer and to have their scientists use our software in their early discovery programs”
03-Mar-2021
Iktos announced the application of Iktos Artificial Intelligence technology for de novo design to selected Pfizer small-molecule discovery programs. Over the last few years, phenomenal advances in AI algorithmic development and computational power have enabled innovative approaches in ...
Generative modelling AI technology enables rapid and cost-effective design of novel drugs
15-Mar-2019
Merck announced a collaboration agreement with Iktos, for the use of its generative modelling artificial intelligence (AI) technology, in order to facilitate the rapid and cost-effective discovery and design of promising new compounds. “This agreement is another illustration of how we aim to ...
